Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-01-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司第九届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting results, and decisions such as changing the accounting firm, approving related party transactions, adjusting senior management positions, and calling a shareholders meeting. It includes no financial statements or detailed financial data, but rather governance and management decisions. The document is relatively short (2241 characters) and serves as an official notice of board decisions. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2024-01-09 Chinese
金陵药业股份有限公司监事会关于拟变更解决同业竞争承诺事项的书面审核意见
Board/Management Information Classification · 85% confidence The document is a written supervisory board opinion regarding a proposed change in the resolution of competitive business commitments, referencing relevant laws and company articles. It is a formal opinion or statement from the supervisory board, not a financial report, earnings release, or regulatory filing. It does not announce voting results, changes in management, nor is it a call transcript or capital update. It is a governance-related document expressing the supervisory board's review and approval to submit the matter to the shareholders' meeting. Therefore, it fits best under Board/Management Information (MANG) as it relates to governance and board-level decisions.
2024-01-09 Chinese
金陵药业股份有限公司关于公司控股股东及其全资子公司拟变更解决同业竞争承诺的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the proposed change in the commitment to resolve competition issues between the company and its controlling shareholder and its wholly-owned subsidiary. It details the background of the original commitment, the current status, reasons for the change, and the new commitment terms. It also includes approvals from the independent directors, board of directors, and supervisory board, and mentions that the matter will be submitted to the shareholders' meeting for approval. The document is a formal announcement about changes in commitments related to corporate governance and shareholder relations, not a full financial report, audit, or earnings release. It does not contain financial statements or detailed financial data but rather governance and management-related information about controlling shareholder commitments and related party transactions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or important information related to the company's board or senior management and related governance matters.
2024-01-09 Chinese
金陵药业股份有限公司2024年第一次独立董事专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is titled as the "2024 First Independent Directors Special Meeting Review Opinions" of Jinling Pharmaceutical Co., Ltd. It contains the independent directors' review opinions on specific company matters such as related party transactions and changes in competition commitments. The content is focused on governance and compliance with laws and regulations, reflecting the independent directors' oversight role. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal opinion report from the board's independent directors rather than a full annual or interim report, audit report, or earnings release. It is not a simple announcement or certification but a governance-related document. Therefore, the best fitting category is Board/Management Information (MANG), which covers announcements related to board activities and management decisions.
2024-01-09 Chinese
金陵药业股份有限公司关于签署《收购意向书》暨关联交易提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Jinling Pharmaceutical Co., Ltd. regarding the signing of a Letter of Intent for an acquisition and related party transaction. It describes the strategic intent, parties involved, transaction background, and outlines the steps and conditions for the acquisition of fund shares and subsequent dissolution and equity distribution. The document includes financial data of related parties and the fund, legal and regulatory compliance notes, and risk disclosures. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement of a significant capital transaction involving related parties. The document is lengthy (over 8,000 characters) and contains substantive details about the transaction, but it is not a report or presentation. It fits best under the category of Capital/Financing Update (CAP), as it provides an update on a major financing and acquisition-related transaction involving share acquisition and restructuring of ownership stakes.
2024-01-04 Chinese
金陵药业股份有限公司关于购买公司及董事、监事、高级管理人员责任险的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the purchase of directors and officers liability insurance by the company and its board members. It includes details about the insurance plan, the decision-making process, and the submission of the matter to the shareholders' meeting for approval. The document is short (1133 characters) and serves as a formal announcement of a corporate governance-related decision rather than a detailed report or financial statement. It does not contain financial data, earnings, or regulatory certifications. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2023-12-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.